American Society of Hirudotherapy

Thrombin induced tumour growth - pharmacological control

Research article published in Hamostaseologie (2007)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportDrug DevelopmentSalivary PharmacologyNowak G et al. · Hamostaseologie, 2007

Abstract

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells. Thrombin is permanently available in tumour micro environment; meizothrombin is generated from prothrombin at a tumour specific activation complex and can influence tumour cell growth via PAR-1 and 7-transdomain protein receptor signalling pathway, too. PEG-coupled direct thrombin inhibitors that possess special pharmacokinetic characteristics and that have been designed for long lasting efficacy in extracellular space, control serine proteinase activity in tumour micro environment and therefore they own a high potential anti-tumour efficacy. In xenographic tumour models this new substance class has shown a significant carcinostatic effect.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeEnglish AbstractJournal Article
Indexed MeSH termsAmino Acid SequenceCell DivisionHirudinsHumansModels, MolecularMolecular Sequence DataNeoplasmsProtein ConformationReceptor, PAR-1Receptors, ThrombinSignal TransductionThrombin

Summary

The central enzyme of blood coagulation, the serine proteinase thrombin, is capable to modify the growth of tumour cells by interaction with protease activated receptors 1 and 4 of the tumour cells.

Why This Matters for Hirudotherapy

This abstract examines how thrombin modifies tumor cell growth through protease-activated receptors (PAR-1 and PAR-4) and tests PEG-coupled direct thrombin inhibitors as a means of controlling thrombin activity in the tumor microenvironment, reporting significant carcinostatic effects in xenographic tumor models. This work is tangentially relevant to the broader pharmacology of thrombin inhibition. However, the abstract makes no mention of hirudin, leeches, or any leech-derived compounds. The study involves a PEG-coupled inhibitor class, not hirudin or related molecules, so the connection to hirudotherapy or the leech secretome is not established by this abstract.

Citation

Thrombin induced tumour growth - pharmacological control

Nowak G et al. · Hamostaseologie, 2007

DOIPubMed

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.